Recruiting
Early Phase 1

Vascular Beta3 Adrenergic Receptors

Sponsor:

University of Missouri-Columbia

Code:

NCT07674680

Conditions

Women

Aging

Menopause

Eligibility Criteria

Sex: Female

Age: 18 - 70

Healthy Volunteers: Accepted

Interventions

Placebo

Gemtesa

Study Details

Brief summary:

To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.

Conditions

Women

Aging

Menopause

Study ID

NCT07674680

Start date

Jul 31, 2026

Status verified date

Sep, 2026

Completion date

May, 2029

Anticipated

Primary completion date

May, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 70

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Healthy women,
  • Assigned female at birth,
  • 18-70 years of age,
  • Body mass index <18 or ≥30 kg/m2,

Exclusion Criteria:

  • Assigned male at birth,
  • Pregnancy,
  • Breastfeeding,
  • History of hormone replacement therapy, chemical menopause, or oophor-ectomy
  • Polycystic ovarian syndrome or Primary ovarian insufficiency,
  • Current smoking/Nicotine use,
  • Blood pressure ≥140/90 mmHg,
  • Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy,
  • Nerve/neurologic disease,
  • Cardiovascular, hepatic, renal, respiratory disease,
  • Hypersensitivity to nitroglycerin,
  • Diabetes,
  • Communication barriers,

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Cold pressor test

Participants will be exposed to the cold pressor test (ice water on the foot).

experimental: Flow Mediated Dilation

Participants will be exposed to the high-resolution ultrasound following inflation of a cuff around the forearm.

Interventions

Placebo

Participants will receive a placebo in pill form.

Gemtesa

Participants will receive oral gemtesa (75 mg).

Primary outcome measure

  • Blood flow [ Time Frame: Change from baseline to minute 2. ]

Central Contacts and Locations

Central contacts

Jacqueline Limberg Associate Professor

1-573-882-2544limberglab@missouri.edu

Locations

University of Missouri

Recruiting

Columbia, Missouri, United States, 65211

Contacts

Jacqueline Limberg Associate Professor

1-573-882-2544limberglab@missouri.edu

More Information

Sponsor

University of Missouri-Columbia

Last update posted

Sep 10, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-11. This information was provided to ClinicalTrials.gov by University of Missouri-Columbia on 2026-09-10.